Concussion substitute Yuzvendra Chahal took three wickets as India beat Australia by 11 runs in the first Twenty20 match in Canberra on Friday but the win was soured by an apparent hamstring injury to all-rounder Ravindra Jadeja.
In a contest laced with controversy, Jadeja top-edged into his helmet in the final over but was not tested for concussion on the field at Manuka Oval.
He ended up scoring a valuable nine runs off the last three deliveries to push his team to a defendable total of 161 for seven.
Jadeja, however, was ruled out during the innings break, and Australia coach Justin Langer had a heated argument with match referee David Boon before the home side began its chase at Manuka Oval.
Legspinner Chahal rubbed salt into Australia's wounds by removing captain Aaron Finch for 35 and star batsman Steve Smith for 12 in quick succession to swing the momentum back to India.
He returned to dismiss Matthew Wade for seven with the last ball of his quota, the wicketkeeper slog-sweeping to captain Virat Kohli at deep midwicket.
"Obviously it's a great feeling," Chahal beamed after being named man-of-the-match.
"It's my pleasure to take their wickets. They know the conditions very well and I bowled according to my plans."
India claimed their second successive win of the tour after beating Australia in the third one-day international on Wednesday.
But they will be without Jadeja for the rest of the T20I series, with the Board of Control for Cricket in India (BCCI) confirming the all-rounder had sustained a concussion.
"Jadeja sustained a concussion after being hit on the left side of his forehead in the final over of the first innings of the first T20I against Australia," the BCCI said in a statement.
"The diagnosis was confirmed based on a clinical assessment in the dressing room during the innings break by the BCCI Medical Team.
"Jadeja remains under observation and will be taken for further scans if required based on the assessment on Saturday morning. He will not take any further part in the ongoing T20I series."
Shardul Thakur replaces Jadeja for the two remaining games of the series.
Jadeja had called for a trainer in the 19th over as he struggled to bat with his injury but he gathered himself to hammer 24 runs off the last seven balls faced in his unbeaten 44.
Australia were also left counting the cost, with Finch suffering a muscle injury in the field and hobbling between wickets during his knock.
Australia have already lost opener David Warner to a groin injury for the T20 series and all-rounder Marcus Stoinis has been recovering from a soft tissue injury.
Opener Lokesh Rahul scored a sparkling 51 off 40 balls and left-arm seamer T Natajaran took 3-30 for the tourists, who ended up cruising to victory despite a mixed display in the field, with Finch dropped twice in successive balls.
The second of the three-match series is in Sydney on Sunday.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.